307 filings
Page 8 of 16
8-K
3kpj5q 5u
28 Jun 17
Amicus Therapeutics Submits Japanese New Drug Application for Migalastat for Fabry Disease
12:00am
8-K
fkvwpp
14 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
k6jobalznxwa71
31 May 17
Amicus Therapeutics Receives Rare Pediatric Disease Designation for SD-101 for Patients with Epidermolysis Bullosa
12:00am
8-K
zy23hm2qgj iaj
22 May 17
Other Events
12:00am
8-K
g8hs bcu6y
19 May 17
Amicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study
12:00am
8-K
shousuv5wp
17 May 17
Other Events
12:00am
8-K
mg96dupjw ysj
15 May 17
Regulation FD Disclosure
12:00am
8-K
6w0a hs9v
9 May 17
Amicus Therapeutics Announces First Quarter 2017
12:00am
8-K
mjq tvhsb5
28 Apr 17
Other Events
12:00am
8-K
n9n2o9
3 Apr 17
Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
12:00am
8-K
0c0f1yyhgaq
8 Mar 17
Other Events
12:00am
8-K
zs8a9oyo
1 Mar 17
Amicus Therapeutics Announces Full-Year 2016
12:00am
8-K
l1qarsu lmzute2s
16 Feb 17
Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposiumâ„¢ 2017
12:00am
8-K
fnbgn3e
16 Feb 17
Other Events
12:00am
8-K
n5zq2h2xyuthc bpdo2
15 Feb 17
Amicus Therapeutics Highlights New Fabry Program Data at WORLDSymposiumâ„¢ 2017
12:00am
8-K
jds9ao aasws
15 Feb 17
Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposiumâ„¢ 2017
12:00am
8-K
9hmjqw083u nfd
9 Feb 17
Departure of Directors or Certain Officers
12:00am
8-K
p4p3cvrz 6tqnu
9 Jan 17
Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance
12:00am
8-K
uadpisdts8d1x 3nn
30 Dec 16
Departure of Directors or Certain Officers
12:00am
8-K
0vt3a5st
21 Dec 16
Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full of Option to Purchase Additional Notes
12:00am